Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aquestive Therapeutics, Inc. (AQST : NSDQ)
 
 • Company Description   
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based in NJ, United States.

Number of Employees: 147

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.34 Daily Weekly Monthly
20 Day Moving Average: 3,565,728 shares
Shares Outstanding: 125.51 (millions)
Market Capitalization: $670.23 (millions)
Beta: 1.48
52 Week High: $7.55
52 Week Low: $2.93
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 24.48% 25.03%
12 Week 26.54% 23.85%
Year To Date -17.34% -26.69%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
30 TECHNOLOGY DRIVE
-
WARREN,NJ 07059
USA		 ph: 908-941-1900
fax: -		 investorrelations@aquestive.com http://www.aquestive.com
 
 • General Corporate Information   
Officers
Daniel Barber - President and Chief Executive Officer
Gregory B. Brown - Chairman
A. Ernest Toth, Jr. - Senior Vice President and Chief Financial Officer
Abigail L. Jenkins - Director
John S. Cochran - Director

Peer Information
Aquestive Therapeutics, Inc. (GSAC)
Aquestive Therapeutics, Inc. (CASIF)
Aquestive Therapeutics, Inc. (ALCD.)
Aquestive Therapeutics, Inc. (OMNN)
Aquestive Therapeutics, Inc. (CGPI.)
Aquestive Therapeutics, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 03843E104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/04/26
Share - Related Items
Shares Outstanding: 125.51
Most Recent Split Date: (:1)
Beta: 1.48
Market Capitalization: $670.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 12.39
EPS Growth
vs. Year Ago Period: -28.57%
vs. Previous Quarter: -157.14%
Sales Growth
vs. Year Ago Period: 38.15%
vs. Previous Quarter: -4.34%
ROE
06/30/26 - -
03/31/26 - -
12/31/25 - -
ROA
06/30/26 - -52.40
03/31/26 - -49.33
12/31/25 - -64.46
Current Ratio
06/30/26 - 7.19
03/31/26 - 4.10
12/31/25 - 3.14
Quick Ratio
06/30/26 - 6.74
03/31/26 - 3.85
12/31/25 - 3.01
Operating Margin
06/30/26 - -144.63
03/31/26 - -137.08
12/31/25 - -188.09
Net Margin
06/30/26 - -144.63
03/31/26 - -137.08
12/31/25 - -188.09
Pre-Tax Margin
06/30/26 - -144.63
03/31/26 - -137.08
12/31/25 - -188.09
Book Value
06/30/26 - -0.45
03/31/26 - -0.27
12/31/25 - -0.28
Inventory Turnover
06/30/26 - 2.42
03/31/26 - 2.43
12/31/25 - 2.53
Debt-to-Equity
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Capital
06/30/26 - -
03/31/26 - -
12/31/25 - -
 

Powered by Zacks Investment Research ©